Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
2006/11/01 by A. John Rush, Madhukar H. Trivedi, Stephen R. Wisniewski +15 · 71 citations
Medicine · Psychology · #Treatment of Major Depression #Psychotherapy Techniques and Applications #Digital Mental Health Interventions
paper · doi:10.1176/ajp.2006.163.11.1905
Abstract
OBJECTIVE: This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. METHOD: A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps. Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step. Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase. A score of <or=5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR(16)) (equivalent to <or=7 on the 17-item Hamilton Rating Scale for Depression [HRSD(17)]) defined remission; a QIDS-SR(16) total score of >or=11 (HRSD(17)>or=14) defined relapse. RESULTS: The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase. In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps. CONCLUSIONS: When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.
Cited by
- Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
- Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression
- Using Brain Imaging to Improve Spatial Targeting of Transcranial Magnetic Stimulation for Depression
- Personalized and Circuit-Based Transcranial Magnetic Stimulation: Evidence, Controversies, and Opportunities
- A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression
- Moderators of antidepressant augmentation versus switch in the OPTIMUM randomised controlled trial
- Quality of life and productivity among esketamine responders in a real-world study in Australia and New Zealand
- Symptom profiles at baseline are associated with remission in major depression: a confirmatory analysis of the PANDORA trial
- Patients’ perspectives on political self‐disclosure, the therapeutic alliance, and the infiltration of politics into the therapy room in the Trump era
- Annual Research Review: Neuroimmune network model of depression: a developmental perspective
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
- Cost‐Effectiveness of <scp>rTMS</scp> as a Next Step in Antidepressant Non‐Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches
- The functional role of ERK activity in esketamine's antidepressant effects
- Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
- Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications
- Sex differences in stress-related psychiatric disorders: Neurobiological perspectives
- Computational psychiatry as a bridge from neuroscience to clinical applications
- Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
- Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
- Machine learning for precision psychiatry
- Reward circuitry predicts the effects of fMRI-guided accelerated prolonged iTBS in treatment-resistant depression
- F. prausnitzii potentially modulates the association between citrus intake and depression
- Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
- Precision Psychobiotics for Gut–Brain Axis Health: Advancing the Discovery Pipelines to Deliver Mechanistic Pathways and Proven Health Efficacy
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
- Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial
- Neuroinflammation, Microbiota-Gut-Brain Axis, and Depression: The Vicious Circle
- Methodological Recommendations for Trials of Psychological Interventions
- Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression
- Distinguishing Functional From Syndromal Recovery: Implications for Clinical Care and Research
- Inverse-intensity weighted generalized estimating equations with irregularly measured longitudinal data and informative dropout
- Structural abnormalities associated with poor outcome of a major depressive episode: The role of thalamus
- Regional brain morphology and current antidepressant use: findings from 32 international cohorts from the ENIGMA major depressive disorder working group
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
- Time for united action on depression: a Lancet–World Psychiatric Association Commission
- Polygenic risk scores: from research tools to clinical instruments
- A double-blind, placebo-controlled, randomised withdrawal study of adjunctive brexpiprazole maintenance treatment for major depressive disorder
- Mindfulness-Based Cognitive Therapy: Theory and Practice
- Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
- Gut microbiome signatures associated with depression and obesity
- The “Africanisation” of communication studies
- Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications
- Generalizing Clinical Trials with Convex Hulls
- Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial
- Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
- Machine Learning Approaches for Detecting the Depression from Resting-State Electroencephalogram (EEG): A Review Study
- Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study
- Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. [europepmc]
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. [europepmc]
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. [europepmc]
- Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. [europepmc]
- Major depressive disorder: new clinical, neurobiological, and treatment perspectives. [europepmc]
- A "SMART" design for building individualized treatment sequences. [europepmc]
- Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. [europepmc]
- A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. [europepmc]
- Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. [europepmc]
- Bipolar disorder diagnosis: challenges and future directions. [europepmc]
- Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. [europepmc]
- Default mode network mechanisms of transcranial magnetic stimulation in depression. [europepmc]
- Sex differences in stress-related psychiatric disorders: neurobiological perspectives. [europepmc]
- Pathogenesis of depression: Insights from human and rodent studies. [europepmc]
- The role of inflammation in depression: from evolutionary imperative to modern treatment target. [europepmc]
- Computational psychiatry as a bridge from neuroscience to clinical applications. [europepmc]
- Role of neuroinflammation in neurodegenerative diseases (Review). [europepmc]
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites. [europepmc]
- Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. [europepmc]
- Mechanisms of ketamine action as an antidepressant. [europepmc]
- Psychedelics Promote Structural and Functional Neural Plasticity. [europepmc]
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. [europepmc]
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. [europepmc]
- The Role of Inflammation in Depression and Fatigue. [europepmc]
- Polygenic risk scores: from research tools to clinical instruments. [europepmc]
Related